Table 1.
Characteristics of statins users with a CPK measurement or rhabomyolysis and matched statin users without CPK measurement
| Characteristics | Normal CPK (n = 103 610) | Matched controls to normal CPK patients (n = 103 610) | One to two timwa ULN CPK (n = 18 892) | Two to three times ULN CPK (n = 2950) | Three to four times ULN CPK (n = 863) | 4-5x ULN CPK (n = 333) | 5-10x CPK (n = 379) | 10+x ULN CPK (n=182) | Rhabdomyolysis (n = 59) |
|---|---|---|---|---|---|---|---|---|---|
| Women (%) | 50735 (49.0%) | 50735 (49.0%) | 6482 (34.3%) | 798 (27.1%) | 253 (29.3%) | 94 (28.2%) | 108 (28.5%) | 72 (39.6%) | 22 (37.3%) |
| Mean age (years) (SD) | 65.8 (11.2) | 65.8 (11.3) | 64.2 (11.2) | 63.7 (11.7) | 63.4 (11.7) | 64 (12.8) | 62.6 (13.3) | 64.3 (14.6) | 69.6 (15.9) |
| Number of non-statin prescriptions in three months before (standard deviation) | 11.2 (12.3) | 11.9 (13.4) | 10.5 (11.7) | 11.1 (11.4) | 11.4 (11) | 12.3 (12.6) | 13.4 (17.7) | 15.4 (17.8) | 25.8 (26.9) |
| Recent prescribing of | |||||||||
| Antihypertensives (%) | 73708 (71.1%) | 75911 (73.3%) | 13279 (70.3%) | 2087 (70.7%) | 624 (72.3%) | 244 (73.3%) | 280 (73.9%) | 136 (74.7%) | 47 (79.7%) |
| CYP3A4 interacting drugs (%) | 8117 (7.8%) | 8003 (7.7%) | 1293 (6.8%) | 218 (7.4%) | 74 (8.6%) | 39 (11.7%) | 39 (10.3%) | 17 (9.3%) | 9 (15.3%) |
| Non- CYP3A4 interacting drugs (%) | 5990 (5.8%) | 6206 (6.0%) | 1129 (6%) | 190 (6.4%) | 59 (6.8%) | 22 (6.6%) | 33 (8.7%) | 17 (9.3%) | 9 (15.3%) |
| Oral corticosteroids (%) | 3998 (3.9%) | 3826 (3.7%) | 481 (2.5%) | 99 (3.4%) | 29 (3.4%) | 10 (3%) | 21 (5.5%) | 12 (6.6%) | 5 (8.5%) |
| Recent myalgia (%) | 5675 (5.5%) | 138 (0.1%) | 1057 (5.6%) | 180 (6.1%) | 51 (5.9%) | 25 (7.5%) | 30 (7.9%) | 25 (13.7%) | 4 (6.8%) |
| Recent renal failure (%) | 1792 (1.7%) | 839 (0.8%) | 334 (1.8%) | 69 (2.3%) | 19 (2.2%) | 5 (1.5%) | 8 (2.1%) | 8 (4.4%) | 32 (54.2%) |
| Medical history of | |||||||||
| Hyperthyroidism (%) | 1823 (1.8%) | 1845 (1.8%) | 276 (1.5%) | 38 (1.3%) | 16 (1.9%) | 10 (3%) | 10 (2.6%) | 7 (3.8%) | 0 (0%) |
| Hypothyroidism (%) | 8920 (8.6%) | 8666 (8.4%) | 1461 (7.7%) | 235 (8%) | 82 (9.5%) | 38 (11.4%) | 28 (7.4%) | 23 (12.6%) | 5 (8.5%) |
| Chronic obstructive pulmonary disease (%) | 5743 (5.5%) | 6434 (6.2%) | 975 (5.2%) | 157 (5.3%) | 50 (5.8%) | 23 (6.9%) | 24 (6.3%) | 16 (8.8%) | 3 (5.1%) |
| Diabetes mellitus (%) | 23237 (22.4%) | 24793 (23.9%) | 4391 (23.2%) | 720 (24.4%) | 223 (25.8%) | 95 (28.5%) | 83 (21.9%) | 43 (23.6%) | 22 (37.3%) |
| Type of statin | |||||||||
| Simvastatin (%) | 69463 (67.0%) | 70413 (68.0%) | 12482 (66.1%) | 1881 (63.8%) | 579 (67.1%) | 216 (64.9%) | 248 (65.4%) | 107 (58.8%) | 45 (76.3%) |
| Atorvastatin (%) | 24599 (23.7%) | 24514 (23.7%) | 4629 (24.5%) | 744 (25.2%) | 196 (22.7%) | 76 (22.8%) | 87 (23.0%) | 54 (29.7%) | 8 (13.6%) |
| Cerivastatin (%) | 225 (0.2%) | 183 (0.2%) | 31 (0.2%) | 5 (0.2%) | 0 (0%) | 1 (0.3%) | 2 (0.5%) | 0 (0%) | 0 (0%) |
| Fluvastatin (%) | 735 (0.7%) | 727 (0.7%) | 123 (0.7%) | 24 (0.8%) | 8 (0.9%) | 4 (1.2%) | 4 (1.1%) | 1 (0.5%) | 1 (1.7%) |
| Pravastatin (%) | 4855 (4.7%) | 4799 (4.6%) | 795 (4.2%) | 142 (4.8%) | 42 (4.9%) | 14 (4.2%) | 17 (4.5%) | 10 (5.5%) | 2 (3.4%) |
| Rosuvastatin (%) | 3733 (3.6%) | 2974 (2.9%) | 832 (4.4%) | 154 (5.2%) | 38 (4.4%) | 22 (6.6%) | 21 (5.5%) | 10 (5.5%) | 3 (5.1%) |